Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?

RMD Open. 2022 May;8(1):e002203. doi: 10.1136/rmdopen-2022-002203.

Authors

Andrew J Laster¹, Gordon K Lam², Heather S Gladue², Ahmad A Kashif², Erin P Siceloff², Virginia D Lackey², Cheryl R Robertson², Ashley L Toci², Leonard H Calabrese³

Affiliations

¹ Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, USA ajlaster@aocc.md.
² Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, USA.
³ Rheumatology/Immunology, Cleveland Clinic, Cleveland, Ohio, USA.

No abstract available

Keywords: COVID-19; arthritis, rheumatoid; biological therapy; methotrexate; vaccination.

Publication types

Letter

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Immunomodulating Agents
Rheumatic Diseases* / drug therapy
SARS-CoV-2

Substances

COVID-19 Vaccines
Immunomodulating Agents